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ABSTRACT
CD46 is a complement inhibitor membrane cofactor which also acts as a receptor 
for various microbes, including species B adenoviruses (Ads). While most Ad gene 
therapy vectors are derived from species C and infect cells through coxsackie-
adenovirus receptor (CAR), CAR expression is downregulated in many cancer 
cells, resulting inefficient Ad-based therapeutics. Despite a limited knowledge on 
the expression status of many cancer cells, an increasing number of cancer gene 
therapy studies include fiber-modified Ad vectors redirected to the more ubiquitously 
expressed CD46. Since our finding from tumor microarray indicate that CD46 was 
overexpressed in cancers of the prostate and colon, fiber chimeric Ad5/35 vectors 
that have infection tropism for CD46 were employed to demonstrate its efficacy in 
colorectal cancers (CRC). CD46-overexpressed cells showed a significantly higher 
response to Ad5/35-GFP and to Ad5/35-tk/GCV. While CRC cells express variable 
levels of CD46, CD46 expression was positively correlated with Ad5/35-mediated GFP 
fluorescence and accordingly its cell killing. Injection of Ad5/35-tk/GCV caused much 
greater tumor-suppression in mice bearing CD46-overexpressed cancer xenograft 
compared to mock group. Analysis of CRC samples revealed that patients with positive 
CD46 expression had a higher survival rate (p=0.031), carried tumors that were 
well-differentiated, but less invasive and metastatic, and with a low T stage (all 
p<0.05). Taken together, our study demonstrated that species B-based adenoviral 
gene therapy is a suitable approach for generally CD46-overexpressed CRC but would 
require careful consideration preceding CD46 analysis and categorizing CRC patients.
INTRODUCTION
Colorectal cancers (CRC) are the third most common 
cancer in the United States, with an estimated 132,700 new 
cases in 2015 [1]. Metastatic CRC is the second leading 
cause of death from cancer with an estimated 49,700 
deaths in 2015, largely due to the poor clinical response 
of tumors to conventional chemotherapeutics. Application 
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of adenoviral gene therapy has been receiving interest to 
overcome poor therapeutic efficacy of conventional cancer 
treatment [2, 3].
Adenovirus (Ad) has been attractive tool for cancer 
gene therapy as a result of its high transduction efficiency 
and a large quantity of information acquired from many 
clinical trials. Its efficiency for cancer gene therapy, 
however, has been limited mainly due to the lack of 
cancer cell targeting, presence of neutralizing antibodies, 
and hepatotoxicity [4–7]. So far, 57 serotypes of human 
Ads have been identified, which are divided into species 
A to G. The most commonly used Ad vectors are based on 
species C Ad5, which primarily binds to the coxsackie- 
adenovirus receptor (CAR) [8]. Many tumor cells, 
however, express relatively low levels of CAR, which 
essentially renders the tumor cell resistant to Ad5 infection 
[4, 5]. Moreover, as most adults are immune to Ad5, a 
high dose is required for effective therapy [6]. Species 
B adenoviruses are subdivided into B1 and B2. The B1 
subspecies includes Ad3, Ad7, Ad16, Ad21, and Ad50 
whereas the B2 subspecies includes Ad11, Ad14, Ad34, 
and Ad35. Viral tropism of species B to cancer cells, 
dendritic cells, and hematopoietic stem cells is broader 
than that of species C [9, 10]. Species B adenoviruses bind 
to different cell surface receptors than other members of 
the Ad family. These include CD46 for Ad3/11/35 [11–13] 
and desmoglein 2 (Dsg2) for Ad3/7/11/14 [14, 15].
CD46 is a type I membrane protein that plays an 
important inhibitory role in complement-dependent 
cytotoxicity (CDC) [16]. Human cells most commonly 
express 3 types of complement restriction factors (also 
called membrane cofactor proteins): CD55, CD46, and 
CD59. CD46 protects host cells from CDC by binding 
to C3b, inactivating C3b and C4b, and preventing 
subsequent degradation by the plasma serine protease 
[17]. CD46 also acts as a receptor for numerous 
pathogenic microbes, including group B adenoviruses 
[18]. CD46 is also overexpressed in some human cancers, 
including lymphomas, breast cancers, ovarian cancers, 
hepatocellular carcinomas [19–22], thus protecting cancer 
cells from the complement system. Therefore, group B 
Ads are attractive gene therapy vectors since they can 
overcome the limitations in tumor transduction efficacy 
through utilizing more ubiquitously expressed CD46. 
More recently, there is an increasing number of studies 
using chimeric adenoviruses containing the Ad35 fiber 
knob in the context of the Ad5 backbone to enhance the 
antitumor capability. In fact, these chimeric vectors with 
modified fiber knobs have been reported to improve gene 
transduction efficiency [6, 23–29].
Despite the increasing number of cancer therapeutic 
approaches using these chimeric adenoviral vectors, the 
detailed expression status of CD46 as a viral target in 
human cancers remains to be elucidated. In this study, we 
first investigated the expression levels of CD46 in various 
tumors using tissue microarrays, demonstrating that 
CD46 overexpression was prevalent in prostate cancers 
(PCa) and colorectal cancers (CRC). We then focused 
on CD46 expression in selected CRC patient samples 
to determine the correlation between CD46 and clinical 
outcomes. Several CRC cell lines characterized for their 
CD46 expression levels were further analyzed for viral 
transduction and viral cell toxicity using Ad5/35-GFP and 
Ad5/35-tk, respectively. The tumor-specific killing effect 
mediated by Ad5/35-tk in combination with ganciclovir 
(GCV) was also investigated in xenograft nude mouse 
models.
RESULTS
CD46 is overexpressed in cancers of the 
colorectum and prostate
In order to profile the expression level of CD46 
in human cancers, tumor tissue microarray slides were 
stained with anti-CD46 antibodies. Within the pool of 
normal tissues including brain, peripheral nerve, adrenal 
gland, thyroid gland, bone marrow, spleen, lymph node, 
lung, heart, skeletal muscle, salivary gland, pancreas, 
stomach, small intestine, colon, mesothelium, kidney, 
ovary, prostate, testis, and uterus, immunoreactivity was 
observed only in the liver (data not shown). In tumor 
tissues, CD46 was most prevalently expressed in cancers 
of the colon and prostate, in which more than 35 % of the 
tumors overexpressed CD46, while CD46 expression was 
less than 11% in other tumors (Table 1 and Supplementary 
Figure S1). CD46 expression in both prostate and colon 
cancers is significantly higher than tumors from other 
origins (Q=56.85 with 7df, p<0.0001 Cochran-Mantel-
Haenszel statistics based on Row Mean Scores Differ). 
Considering that the actual tumor cells represent only a 
small fraction within the tumor microarray, CD46 was 
quite highly expressed in both PCa and CRC. CD46 has 
been implicated in the development and progression of 
several cancer types. Elevated expression of CD46 has 
been observed in medulloblastomas, breast cancers, and 
CRCs [30–32]. Although the expression level of CD46 
was significantly higher in CRC tissues compared with 
the adjacent normal colon tissues, CD46 expression was 
not associated with colon cancer progression [31]. Due to 
the on hand availability of CRC tissues and to difficulties 
in evaluating the notoriously heterogeneous population of 
PCa, we limited our further studies to CRC.
Redirection of Ad5 vector to CD46 with Ad35 
fiber knob enhances the transduction
To evaluate whether CD46 expression levels 
correlate with transduction of an adenoviral vector 
utilizing CD46 as an attachment receptor, we generated 
a chimeric Ad5/35-GFP virus, in which the fiber 
knob domain of the Ad5 capsid was replaced with the 
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fiber knob of the species B Ad35. To characterize the 
transduction efficiency of the Ad5/35-GFP virus, either 
parental baby hamster kidney (BHK) cells, or BHK 
cells ectopically overexpressing CAR or CD46 were 
used [13]. High expression levels of CD46 in the BHK-
CD46 cells were confirmed by Western blot (Figure 1A) 
and flow cytometric analyses (Figure 1B). Minor bands 
shown in WT- and CAR-BHK cells seem to result from 
antibody cross-reaction. To determine whether there 
is a correlation between CD46 and efficiency of gene 
transduction, the BHK cells were infected with Ad5/35-
GFP using multiplicity of infection (MOI) from 5 to 100. 
GFP-positive cells were monitored 24 hrs post infection 
by fluorescence microscopy (Supplementary Figure 
S2A), or by flow cytometry. There was a significant 
dose-dependent increase in the transduction efficiency of 
BHK-CD46 cells compared to either wild type or BHK-
CAR cells (p<0.01 by 2-way ANOVA) (Figure 1C). We 
further tested the correlation between the cytotoxic effect 
of the Ad5/35 virus and CD46 expression using Ad5/35-
tk in combination with GCV. Cells were infected with 
Ad5/35-tk (5-20 MOI) and treated with GCV (10-250 
μg/ml). MTT assays performed after four days of GCV 
treatment revealed that reduction in cell proliferation was 
greater in BHK-CD46 cells compared to wild type and 
BHK-CAR cells in an MOI dependent manner (p<0.01 
by 2-way ANOVA) (Figure 1D). Most notably, there was 
an almost 80 % reduction in BHK-CD46 cell proliferation 
at 20 MOI and 100 μg/ml GCV (18.02 ± 3.20) compared 
to a 15-18 % reduction in both control cells (81.59 ± 2.95 
for BHK-WT cells, 84.91±3.44 for BHK-CAR cells) 
(p<0.01). These results suggest that CD46 expression in 
BHK cells promotes Ad35 fiber knob mediated viral gene 
transduction and its viral killing efficacy.
Ad5/35 efficiently transduces gene expression in 
colon cancer cells
To date, the role of CD46 in species B adenoviral 
gene transfer in CRC has not been thoroughly documented. 
According to Silver et al. [33], CD46 was abundantly 
expressed in all CRC cells. However these cells revealed 
variable transduction efficiencies when using species 
B Ad11 which binds to both CD46 and Dsg2. When we 
analyzed CD46 expression levels in five commonly used 
CRC cell lines, including HT-29, HCT-116, DLD-1, Caco-2, 
and SW620 by Western immunoblotting, all cells expressed 
abundant CD46 (Figure 2A). When cells were used for 
adenoviral transduction with Ad5/35-GFP, most cells 
responded to viral gene transduction in a dose-responsive 
manner, especially DLD-1 (p<0.01) (Figure 2B). Compared 
to HT-29, Caco-2, and SW620 cells, majority of DLD-1 
and HCT-116 were highly responsive to viral transduction 
(post-hoc Tukey test). To determine the correlation between 
the expression level of CD46 and Ad5/35-mediated gene 
transduction, two color flow cytometric studies were 
performed using RFP for CD46 (Figure 2C) and GFP for 
or Ad5/35-GFP-mediated reporter expression (Figure 
2D). When positive cells were demonstrated based on the 
mean fluorescence, CD46 level and viral gene transduction 
efficiency were almost equivalent, showing that there 
was no difference between CD46 expression level and 
adenoviral GFP transduction among cells (p=0.267 
by 2-way ANOVA). When double positive cells were 
compared based on cell percentage, CD46 expression 
correlated well with adenoviral gene transduction in 
most CRC cells except HCT-116 (Pearson’s correlation 
coefficient r=0.586, p=0.022)(Figure 2E). In HCT-116 cells, 
Ad5/35-mediated gene transduction was high despite the 
Table 1: Score of CD46 expression in human tumors
Tumor types Score of CD46 expression*
0 1 2 3 0-1** 2-3** total
Brain tumor 21 0 0 0 21 0 (0 %) 21
Melanoma 17 1 1 1 18 2 (10 %) 20
Ovarian cancer 25 1 1 0 26 1 (3.7 %) 27
Lymphoma 39 1 2 0 40 2 (4.8 %) 42
Lung cancer 41 9 4 2 50 6 (10.7 %) 56
Breast cancer 34 1 1 2 35 3 (7.9 %) 38
Colorectal cancer 24 7 13 4 31 17 (35.4 %)# 48
Prostate cancer 21 12 17 2 33 19 (36.5 %)# 52
*, CD46 expression was scored as followed: 0, no; 1, low and focal; 2, moderate; 3, high
**, Scores were categorized by 0-1 as normal expression and 2-3 as overexpression
#, CD46 expression is significantly higher than tumors from other origins (Q=56.85 with 7df, p<0.0001 Cochran-Mantel-
Haenszel statistics based on Row Mean Scores Differ)
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Figure 1: Gene transduction efficacy of Ad5/35 is enhanced in CD46-expressing cells. A. Western blot analysis of CD46 
expression in parental rodent BHK cells or BHK-CAR and BHK-CD46 cells which ectopically express the Ad receptors CAR and CD46, 
respectively. B. Flow cytometric analysis of CD46 expression in BHK, BHK-CAR and BHK-CD46 cells. C. Transduction analysis of 
BHK, BHK-CAR and BHK-CD46 cells using different doses of Ad5/35-GFP. Cells were analyzed for GFP reporter expression 24 hrs post 
transduction by flow cytometry. Numbers in parentheses indicate percentage of GFP positive cells. D. Cell killing assay in BHK, BHK-
CAR and BHK-CD46 cells transduced with Ad5/35-tk and treated with GCV for 4 days. Cytotoxicity was analyzed by the MTT assay. Error 
bars represent SEM. Statistics: C-D, p<0.01 by 2-way ANOVA.
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low to medium level of CD46 expression. High reporter 
expression was also confirmed by fluorescence microscopy 
(Supplementary Figure S2B). This suggests that in HCT-
116 cells the level of Ad5/35-mediated gene expression 
was influenced by additional factors like secondary integrin 
receptors or by enhanced cell-specific promoter activity. 
However, our results were consistent with a previous report, 
which demonstrated that Ad11 induced more cytotoxicity 
in DLD-1, HCT-116, and HT-29 cells than in SW620 cells 
[34].
To link the Ad5/35-mediated gene transduction 
efficiency to viral cytotoxicity, the five CRC cell lines 
were treated with Ad5/35-tk in combination with GCV 
followed by cell proliferation assays 5 days post infection. 
As shown in Figure 3, cytotoxic effects induced by these 
treatments were significantly greater in HCT-116, DLD-1, 
and Caco-2 cells than in HT-29 and SW620 cells (p<0.01 
by 2-way ANOVA). These results were consistent with 
the CD46 expression levels and virus-mediated gene 
transduction efficiencies shown in Figure 2C and 2D, 
respectively.
CD46 promotes suicide gene therapeutics against 
human cancer cells in vivo
To test the in vivo cell killing efficacy of CD46-
utilizing Ad5/35-tk, CD46-overexpressing human 
A549 human lung adenocarcinoma cells and M010119 
melanoma cells were used. In these cells, endogenous 
CD46 expression levels were further increased following 
transduction with a lentiviral expression construct 
resulting in about 2-fold increase for A549 cells, and 
9-fold increase for M010119 cells [35](also in unpublished 
data). CD46 overexpression in these cells was confirmed 
by Western blot (Supplementary Figure S3A). By the MTT 
proliferation assay, treatment with Ad5/35-tk plus GCV 
more effectively killed CD46-overexpressing A549 cells 
compared to wild type cells (p<0.01 by 2-way ANOVA) 
(Figure 4A–4B). There was a more than 50 % reduction 
in A549-CD46 cell proliferation at 20 MOI and 100 μg/
ml GCV (37.66 ± 3.02) compared to that in control cells 
(75.74 ± 3.11). To further confirm the therapeutic effect 
of CD46-utilizing Ad5/35-tk/GCV on tumor growth in 
vivo, CD46-overexpressing A549 and parental A549 
Figure 2: CD46 expression analysis and Ad5/35-mediated gene transduction in colorectal cancer cell lines. A. CD46 
expression in colon cancer cell lines was analyzed by Western blot analysis. B. CD46-positive cells were detected by flow cytometry 
in response to different dose of Ad5/35-GFP. C-E. Colon cancer cells were applied to flow cytometry to demonstrate intensity of CD46 
expression (C) or Ad5/35-mediated reporter transduction (D). Percentage of cells double-stained with CD46 and GFP was shown in E. 
Error bars represent SEM. Statistics: B, p<0.01 by 1-way ANOVA and post-hoc Tukey test; C-D, p=0.267 by 2-way ANOVA.
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cells were injected subcutaneously into the backs of nude 
mice. When tumor volumes reached around 150 mm3, 
1.5 × 108 plaque-forming units (PFU) of Ad5/35-tk were 
injected intratumorally on days 1 and 6. Then, 75 mg/
kg of GCV was administered intraperitoneally on days 
2–12. Compared to the control group, the CD46-A549 
cells-injected group showed a dramatic decrease in tumor 
volume at 18 days after virus inoculation (p=0.005 by 
repeated-measures ANOVA) (Figure 4C–4D). Average 
tumor volume in the CD46-A549 cells-injected group was 
387.33 ± 57.83 mm3, whereas average tumor volume in the 
wild type A549 cells-injected group was 821.39 ± 191.3 
mm3. In contrast, cell culture growth rates of CD46-A549 
and control cells were not altered significantly without 
Figure 3: Ad5/35-tk-mediated enhancement of in vitro cytotoxicity in CRC cells. Cells were seeded onto 24-well plates and 
incubated overnight. Subsequently, cells were transduced with Ad5/35-tk at the indicated MOIs ranging from 0 to 20. Varying concentrations 
of GCV were added the next day and MTT in vitro proliferation assays were performed 5 days post infection. DLD-1, Caco-2, and HCT-116 
cells more effectively responded to the cytotoxic effect of Ad5/35/GCV than HT-29 and SW620 cells. Error bars represent SEM. Statistics: 
p<0.01 by 2-way ANOVA.
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the treatments (p=0.440) (Figure 4E). Ad5/35-tk in 
combination with GCV was similarly effective in CD46-
overexpressing M010119 melanoma cells both in vitro and 
in vivo (Supplementary Figure S3B-D).
CD46 overexpression indicates better survival of 
patients with CRC
To investigate on a possible correlation between 
CD46 expression and clinico-pathological features 
in patients with CRC, eighty CRC samples from 
patients with a full clinical record were evaluated 
by immunohistochemistry. Samples were scored by 
two investigators including a pathologist. While the 
expression of CD46 in the normal columnar mucosal 
epithelium of the colon was weak (Figure 5A), CD46 
was very highly expressed in both well-differentiated 
(Figure 5B–5C) and poorly differentiated CRCs (Figure 
5D–5E). Immunostaining pattern of CD46 was mostly 
membranous in both normal and cancerous cells. 
Figure 4: CD46 promotes Ad5/35-tk-mediated cytotoxicity for tumor growth in vivo. A-B. Cells were transduced with 
Ad5/35-tk followed by GCV treatment. MTT in vitro proliferation assays were performed 5 days post infection. C-D. Cells were injected 
subcutaneously into nude mice (10-11 mice per group). Intra-tumor injections of Ad5/35-tk viruses (1.5 × 108 PFU) were made twice at the 
indicated time points followed by GCV injections (75 mg/kg) intraperitoneally on days 2–12. Tumor growth was measured by a caliper at 
the indicated time points. E. Cell proliferation of parental A549 and CD46-overexpressing A549 was measured by the MTT assay. Error 
bars represent SEM. Statistics: A-B, p<0.01 by 2-way ANOVA; D, p=0.005 by repeated-measures ANOVA; E, p=0.44 by 1-way ANOVA.
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Majority of poorly differentiated CRCs with a highly 
invasive phenotype did not express CD46 (Figure 5F). 
When CD46 expression of score 2-3 was arbitrarily set 
as positive expression, CD46 expression was positively 
correlated with differentiation (p=0.041) and negatively 
correlated with perineural invasion (p=0.038), tumor 
stage (p=0.003), and distant metastasis (p=0.001) (Table 
2). In addition, the overall survivability of CRC patients 
with positive CD46 expression was significantly higher 
than that of CRC patients with negative CD46 expression 
(χ2=4.678, p=0.031 by the log-rank test) (Figure 6). These 
results suggest that CD46 expression is highly maintained 
in well-differentiated CRC cells and it is lost in poorly 
differentiated aggressive tumor cells.
DISCUSSION
CD46 is a cell-surface regulatory protein that 
prevents lysis of autologous human cells by activated 
complement and is considered to be ubiquitously 
expressed. It has also been demonstrated that CD46 is 
implicated in the development and progression of several 
cancers. CD46 expression is elevated in medulloblastoma 
[32], while CD46 expression has been linked with poor 
prognosis in breast cancer [30]. It has been proposed 
that overexpression of CD46 may serve to protect cancer 
cells from complement-dependent cytotoxicity, thereby 
evading destruction caused by the immune system [36, 
37]. Our study demonstrated that CD46 is generally 
highly expressed in colorectal cancers, and based on this 
phenomenon, species B-based adenoviral gene therapy 
may be better suited than the currently used species C 
adenoviral vector like Ad5. Ad5-based viral therapies 
have several shortcomings, including downregulation 
of its receptor in cancer cells. In fact, many tumor cells 
express relatively low levels of Ad5 receptors, including 
CAR [4, 5, 38]. Our tumor microarray data also showed 
that a low level of CD46 expression in normal liver 
which may imply that adenoviral targeting of CD46 
may results in liver toxicity. However, Ad11, another 
group B adenovirus, induced significantly lower liver 
toxicity in animals in comparison to Ad5, maybe due to 
the lack of interaction of Ad11 with coagulation factor X 
and the consequent absence of hepatocyte infection [39, 
40]. Therefore, chimeric Ad5 vectors that are capable of 
targeting CD46 hold the promise to be more efficient gene 
delivery vehicles than Ad5 vectors with native fibers. In 
order to show that CD46 plays decisive role in species B 
adenoviral gene therapy for CD46-overexpressing colon 
cancers, we developed chimeric Ad5/35 vectors with fiber 
knobs from Ad35 to specifically target CD46 in cancer 
cells.
Generally, CD46 expression was higher in most 
cancer cells compared to CAR expression [34]. In this 
study, we demonstrate that Ad5/35 more efficiently 
delivers GFP and cytotoxic genes to CD46-expressing 
rodent cells compared to CD46 negative parental cells 
or CAR-expressing control cells. The same phenomenon 
was confirmed in various colon cancer cells, where CD46 
expression levels were found to correlate with viral gene 
Figure 5: Immunohistochemical analysis of CD46 expression in patient colorectal cancers. Tumors were analyzed for 
the expression of CD46 by immunostaining. A, normal mucosa. B-C, well- differentiated tumors. D-F, poorly differentiated and highly 
invasive tumors. While CD46 was generally overexpressed in colorectal tumors compared to normal counterparts, some invasive cancers 
showed no expression of CD46. High-powered pictures are shown in inlets of selected areas.
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transduction and cytotoxic effects. Thus, while CD46 
was ubiquitously expressed in all five colon cancer cells 
used in this study, more efficient Ad5/35-mediated gene 
transduction was achieved in HCT-116, DLD-1, and Caco-
2 cells compared to HT-29 and SW620 cells. Cell toxicity 
and proliferation assays also indicated that Ad5/35-tk in 
combination with GCV had the highest cell-killing activity 
in HCT-116, DLD-1, and Caco-2 cells. However, in a study 
using replication competent Ad11, HT-29 cells showed 
high viral transduction and viral cytotoxicity compared 
to other CRC cells including HCT-8 and LS174T [33]. 
Among the CRC cells, HT-29 cells were more sensitive 
to Ad11, while SW620, HCT-116, and DLD-1 cells 
were more sensitive to Ad5 [34]. This may be due to the 
Table 2: Correlation between CD46 expression and clinico-pathological features in patients with colorectal cancers
Total (n=80)
CD46
p-value
Negative (n=33) Positive (n=47)
Age (years) 0.089
< 66.6 37 19 18
≥ 66.6 43 14 29
Sex 0.404
Male 48 18 30
Female 32 15 17
Tumor size (cm) 0.841
< 4.6 45 19 26
≥ 4.6 35 14 21
Histologic type 0.041
Differentiated 72 27 45
Undifferentiated 8 6 2
Lymphovascular invasion 0.536
Negative 54 21 33
Positive 26 12 14
Perineural invasion 0.038
Negative 54 18 36
Positive 26 15 11
Stage 0.003
I / II 40 10 30
III / IV 40 23 17
Depth of invasion (T) 0.96
T1 / T2 24 10 14
T3 / T4 56 23 33
Lymph node metastasis (N) 0.362
N 0 3 2 1
N 1-3 77 31 46
Distant metastasis 0.001
M 0 61 19 42
M 1 19 14 5
Pearson’s χ2 test was used
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presence of other species B adenoviral receptors such as 
desmoglein 2 and receptor X [15, 41]. Many cancer cells 
that originated from the pancreas, prostate, breast, colon, 
ovary, and lung were also Ad11-sensitive [34]. These 
included Hs766T, Capan-1, Capan-2, PaTu 8988s, PC-
3, MCF7, MDA-MB-468, SK-BR-3, and HT-29. Our in 
vivo experiments showed significant growth inhibition of 
ectopically CD46-overexpressing A549 lung cancer and 
M010119 melanoma cells in xenograft mice treated with 
Ad5/35-tk in combination with GCV compared to parental 
cells. Thus, CD46 enhances the cytotoxic effect of species 
B adenoviral gene therapy. In fact, treatment of A549 cells 
with CD46 siRNA resulted in a decrease of transduction 
with Ad3-EGFP [12].
CD46 expression was closely analyzed and 
compared to clinico-pathological parameters, and CD46 
upregulation was observed in highly differentiated, locally 
confined, and non-metastasized CRC. Expression of CD46 
also implies better survivability of patients with CRC. It 
has been reported that CD46 expression was significantly 
higher in colon cancer tissues compared with adjacent 
normal colon tissues. While CD46 was found to have 
no clinical relevance, levels of CD55 and CD59, other 
complement inhibitor membrane cofactor proteins, were 
positively correlated with the differentiation and tumor 
stage in colon cancers [31]. Breast cancers are reported 
to consistently express CD46. Using tissue microarray, 
strong CD46 expression was exhibited by 27% of 
the breast tumors. CD46 expression was significantly 
associated with tumor grade, histological type of tumor, 
and tumor recurrence, but there was no correlation with 
lymph node stage or the presence of vascular invasion. 
Poor-prognosis tumors that lose CD55 and CD59 still 
express CD46. It has been suggested that loss of CD55 
and CD59 could be compensated by expression of CD46 
[21]. Expression of CD46 also represents an independent 
risk factor for disease-free survival and overall survival, 
demonstrating that patients with tumors negative for 
CD46 have an increased progression-free time and overall 
survival time as compared with patients with CD46-
positive tumors. A study demonstrates that breast cancers 
manifest CD46 expression and that it is linked to a less 
favorable prognosis [30].
In this study, we show that CD46 is highly expressed 
in most colorectal tumors, when compared to matching 
normal mucosa. This makes a strong case that colorectal 
cancers represent good targets for CD46-targeting species 
B adenovirus-mediated gene therapy. In fact, chimeric 
Ad5/35 vectors targeting CD46 are known to be better 
tools than vectors targeting CAR for cancer targeted 
gene therapy. While most colon cancer cells express 
substantial amounts of CD46, samples from cancer 
patients show that there is an inverse correlation between 
CD46 expression and clinico-pathological parameters in 
terms of undifferentiation, invasion, metastasis, T stage, 
and survival, suggesting that adenoviral gene therapy may 
not be equally effective in patients with highly advanced 
colorectal cancers. Therefore, suitability of species B 
Figure 6: CD46 expression indicates better survival of CRC patients. Overall survivability was demonstrated by Kaplan-Meier 
curve and measured by the log-rank test (p=0.031).
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adenoviral gene therapy in certain cancer types may need 
careful patient-specific adjustments.
MATERIALS AND METHODS
Patient samples and immunohistochemistry
Multi-tumor tissue microarray slides (TARP2) were 
obtained from the Cooperative Human Tissue Network 
under the Tissue Array Research Program (TARP) of the 
National Cancer Institute, The National Institutes of Health 
(Bethesda, MD, USA). This study also included eighty 
colorectal cancer specimens with normal matching tissues 
from patients who provided informed consent at Chonnam 
National University Hospital. All cases had a clinical 
follow-up for at least 10 years. Immunohistochemistry was 
performed as previously described [42]. Briefly, colorectal 
tumor tissues were deparaffinized and rehydrated in graded 
alcohols and distilled water. Antigens were retrieved by 
heating the tissues in a microwave for 5 min in 10 mM 
sodium citrate buffer (pH 6.0). Endogenous peroxidase 
activity was destroyed with 3% H2O2 in methanol for 
30 min. After blocking nonspecific sites, tissues were 
incubated overnight at 4 °C with anti-CD46 antibody 
(1:200, Origene, Rockville, MD, USA). The slides were 
then incubated with biotinylated anti-rabbit antibody 
(1:400) for 30 min at room temperature. Subsequently, the 
signals were amplified by the horseradish peroxidase-DAB 
detection method (Vector Laboratories, Inc., Burlingame, 
CA, USA). The sections were counterstained with 
hematoxylin for microscopic evaluation. The stained slides 
were evaluated by two different investigators, including 
a pathologist, who were blinded to the patient’s clinical 
features. The intensity of staining was classified into one 
of two grades: positive (medium to strong staining) or 
negative (no to low and focal staining).
Viruses
To construct Ad5/35CMV-GFP, pAd1020sfidA-
CMV-GFP, which was described previously [43], was 
digested with the restriction enzyme SfiI to release 
CMV-GFP-pA and the ψ packaging signal. The fragment 
encompassing the CMV-GFP-pA and the ψ packaging 
signal was recombined with RightZap1.3 (OD260, 
Boise, ID, USA) in HEK293 cells. The virus particles 
were purified by CsCl2 gradient ultracentrifugation. To 
construct Ad5/35CMV-tk, the GFP gene was replaced by 
the thymidine kinase gene (tk).
Cell culture
Human colon cancer cell lines, including HT-29, 
HCT-116, DLD-1, Caco-2, and SW620 were purchased 
from American Type Culture Collection (ATCC, Manassas, 
VA, USA). Baby hamster kidney (BHK) cells expressing 
CAR and CD46, and A549 human non-small cell lung 
cancer cells and A549 cells overexpressing CD46, as well 
as CD46-overexpressing M010119 human melanoma 
cells were described previously [13, 35]. All cells were 
routinely cultured in Dulbecco’s modified Eagle’s medium 
media (DMEM, Invitrogen, CA, USA) supplemented with 
10% heat-inactivated fetal bovine serum (FBS, Invitrogen, 
CA, USA) at 37°C in an atmosphere containing 5% CO2. 
All cultures were fed with fresh medium every 3-4 days.
Western blotting
Cells were grown to 80% confluence and were 
lysed in lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 
1% NP-40, 0.5% DOC and protease inhibitors). Twenty 
μg of total cell lysates were loaded onto 10% SDS-
polyacrylamide gel and separated using a Bio-Rad 
electroporation system. After the proteins were transferred 
to a Immobilon–P membrane (Millipore, Billerica, MA, 
USA), the membranes were blocked with 5% nonfat dry 
milk in Tris-buffered saline containing 0.1% Tween-20 
(TBST) at room temperature for 1 hr. The membrane 
was further incubated overnight with primary antibodies. 
Polyclonal rabbit anti-β-actin antibodies were obtained 
from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, 
USA) and rabbit monoclonal CD46 antibody was obtained 
from OriGene Technologies, Inc. (Rockville, MD, USA). 
After washing with TBST, the membrane was incubated 
for 1 hr with horseradish peroxidase-conjugated secondary 
antibodies. The blots were developed using Immobilon 
Western detection system (Millipore, Billerica, MA, 
USA). Signals were detected and analyzed by using a 
LAS4000 luminescent image analyzer (Fuji, Tokyo, 
Japan).
FACScan analysis
Cells were grown to 80% confluence in 100 mm 
culture dishes. Cells were harvested and incubated with 
rabbit polyclonal CD46 antibody (Origene, Rockville, 
MD, USA) for 30 min at 4°C. After washing, cells were 
further incubated with Alexa 488-labeled anti-rabbit 
IgG (Invitrogen, Carlsbad, CA, USA). Then, cells were 
analyzed by flow cytometry using a FACScan (BD 
Biosciences, San Jose, CA, USA). For viral infectivity 
assays, cells were seeded into 60 mm culture dishes 
and incubated with Ad5/35-GFP virus at different 
multiplicities of infection (MOI 0, 5, 20, 100) at 37°C. 
After 3 hrs, viruses were removed by replacing with fresh 
media. At 24 hrs after infection, cells were harvested and 
washed with PBS. Then, cells were analyzed by flow 
cytometry. Results were analyzed by Kaluza Analysis 
Software (Beckman Coulter, Inc. Brea, CA, USA)
Cell killing assay
For evaluating the in vitro cell killing efficacy of 
Ad5/35- thymidine kinase (Ad5/35-tk) in combination 
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of Ganciclovir (GCV, JHP Pharmaceuticals LLC., MI, 
USA), cells were seeded into a 24-well plate at 1 × 104 
cells per well. The next day, media were changed to 500 
μl of DMEM/ BSA (20 mg/ml) containing Ad5/35-tk with 
various MOI doses (5, 10, 20). At 24 hrs post infection, 
increasing concentrations (0, 10, 50, 100, 150, and 250 
μg/ml) of GCV were added to the wells for 4 days. Cell 
viability was assessed by the MTT assay. Briefly, 50 μl 
of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) solution (0.5 mg/ml) was added to the 
cells and cells were incubated for 4 hrs. The absorbance 
was measured at 570 nm using a microplate reader with 
SOFTmax PRO software (Molecular Devices, Sunnyvale, 
CA, USA).
Immunofluorescence
Cells were grown on glass coverslips in 12-well 
plates. Cells were incubated with Ad5/35-GFP virus 
up to 100 MOI at 37°C. At 3 hrs after infection, cells 
were changed to fresh media. At 24 hrs after infection, 
cells were washed three times with PBS. Coverslips 
were mounted with Prolong Gold anti-fade reagent. 
Photographic images were acquired by using IX51 
fluorescence microscope (Olympus, Tokyo, Japan).
In vivo killing assays
Female nude mice (6 weeks old) were obtained from 
Central Lab. Animal Inc. (Korea). All experiments were 
performed in accordance with our institution’s guidelines 
for animal care. Mice were housed and monitored under 
constant humidity and temperature. Parental A549 or 
A549-GFP-CD46 (5 × 106) cells were subcutaneously 
injected into the flank of mice. When tumor volume 
reached around 150 mm3, 1.5 × 108 plaque-forming units 
(PFU) of Ad5/35-tk were injected intratumorally on 
days 1 and 6. Then, 75 mg/kg of GCV was administered 
intraperitoneally on days 2–12. Tumor size was measured 
every 2 days and tumor volume was calculated using the 
following equation: length × width2 × 0.5.
Statistical analysis
All data were expressed as mean ± standard error 
(SEM) and processed using the SPSS 21.0 software system 
(IBM, Chicago, IL). Viral efficacy comparisons among the 
cells were tested with either one-way or two-way ANOVA. 
Tumor cytotoxicity studies using tumor-bearing mice were 
analyzed by repeated-measures ANOVA. Correlation 
between CD46 expression and various clinico-pathological 
parameters was compared using the Pearson’s χ2 test and 
Fisher’s exact test. Kaplan-Meier method with the log-
rank test was applied to demonstrate survival. Statistical 
significance was achieved when p was less than 0.05.
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